Market Opportunity Target opportunity in fungal infection therapeutics with VIVJOA (oteseconazole) for RVVC, including expansion considerations in China via licensed partner and potential demand for expanding indications to broader fungal pathogens.

Strategic Partners Leverage existing collaboration history with Gedeon Richter and the China licensing deal to identify additional regional or global manufacturing, distribution, or co-development partnerships to accelerate market access and scale.

Lifecycle Adoption Capitalize on FDA designations (QIDP and Fast-Track) to position VIVJOA for accelerated payer discussions, market access strategies, and priority listings with insurers in target geographies.

Product Portfolio Explore expansion opportunities around oral fungal inhibitors and multi-drug resistant fungi, presenting a path to broaden the addressable patient pool beyond RVVC to other difficult-to-treat infections.

Commercial Readiness Highlight existing launch momentum since July 2022 and ongoing digital and commerce infrastructure (Shopify, Squarespace, Salesforce, marketing tech stack) to support rapid sales enablement, market education, and direct-to-consumer or partner-driven campaigns.